Coughing, wheezing and tightness in the chest are are all symptoms of asthma, a chronic disease estimated to affect 400 million people around the world by 2025.
Asthma is a unique condition. A patient may live symptom-free life for many days and months with maintenance therapy. Unfortunately, even those who control their symptoms well can experience a trigger that unexpectedly causes an asthma attack. In minutes, a patient can experience a life-threatening situation that can lead to death.
At Teva Pharmaceutical Industries, a global pharmaceutical company based in Israel, we’ve considered if there are ways to identify early warning signs of an asthma attack. We are developing a digital respiratory disease management system which may enable a proactive, data-driven approach to asthma management.
Many people who live with asthma experience uncontrolled symptoms and frequent attacks, often due to incorrect inhaler use or poor adherence to treatment.
Teva is committed to developing digital respiratory solutions for asthma patients to help them, and their caretakers, control their condition to better manage chronic symptoms. When patients use their digital inhalers and the corresponding software application, they generate data that their doctors can interpret to understand behavior patterns and enable a proactive, systematic and comprehensive approach to chronic disease treatment and management.
The collaboration will combine cloud-connected drug delivery and app technology with more than six billion data points, including integration of data from The Weather Company to incorporate environmental data that could potentially affect asthma patients. Using Watson cognitive processing capabilities and newly developed algorithms these data may be used to calculate the prospective risk of health events, such as an asthma attack. Teva delivers that information directly to caregivers and their patients via an app or other software so they may take a more proactive approach in managing that risk.
Using the IBM Watson Health Cloud will comply with operational and security requirements for health data.
When Teva started looking for a digital solution partner, the company considered several cloud and computing providers. It needed to work with a partner that was able to deliver a global cloud for storing, analyzing and communicating patient data. Teva also needed the capability to perform analysis of multiple data points on millions of patients in real time.
Teva chose IBM as its partner because of the unique capabilities of IBM Watson. Both Teva and IBM have the same aspiration to transform healthcare with digital therapeutic solutions designed to fulfill unmet and emerging patient needs, as well as provide the highest level of care to customers around the world.
As one result of Teva’s global partnership with IBM as a Foundational Life Sciences Partner for IBM Watson Health Cloud, Teva is using IBM Watson Health capabilities to help to improve chronic disease management.
Teva’s vision for the future is that patients will be empowered to better understand and manage chronic diseases, including asthma. They will use data to enable a systematic, comprehensive approach to help them take control of their health conditions and proactively seek the right solution before a health crisis.
In doing so, Teva aims to cut treatment costs by providing patients, payers, healthcare providers and caregivers with relatable data and insights that can inform action.
Learn more about IBM Cloud healthcare solutions.
The post Data enables proactive healthcare, improving chronic disease management appeared first on #Cloud computing news.
Quelle: Thoughts on Cloud
Data enables proactive healthcare, improving chronic disease management
Published by